[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiomyopathy-ischemic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiomyopathy-ischemic":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100558850","preventive-catheter-ablation-for-ventricular-arrhythmias-in-patients-with-end-stage-heart-failure-100558850",false,"NCT06556485","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure","Preventive Catheter Ablation for Ventricular arrhythmiaS in Patients With End-sTage Heart faiLure rEfferred for Heart Transplantation eValuaTion (CASTLE-VT)","CASTLE-VT","Inclusion Criteria:\n\n1. Ischemic cardiomyopathy with left ventricular ejection fraction ≤ 35% (measured in the last 6 weeks prior to enrollment)\n2. Eligible for heart transplantation due to end-stage heart failure\n3. NYHA class ≥ III\n4. Impaired functional capacity or inability to exercise\n5. Indication for ICD therapy due to primary prevention\n6. Implanted ICD or ICD implantation within 3 months after randomization\n7. The patient is willing and able to comply with the protocol and has provided written informed consent\n8. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Previous catheter ablation for ventricular arrhythmias\n2. Previous appropriate ICD-therapy for ventricular arrhythmias\n3. Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 4 weeks prior to enrollment\n4. Untreated hypothyroidism or hyperthyroidism\n5. Woman currently pregnant, breastfeeding, or not using reliable contraceptive measures during fertility age\n6. Mental or physical inability to participate in the study\n7. Listed as \"high urgent\" for heart transplantation\n8. Cardiac assist device implanted\n9. Planned cardiovascular intervention\n10. Life expectancy ≤ 12 month\n11. Uncontrolled hypertension\n12. Requirement for dialysis due to end-stage renal failure","ALL","18 Years","99 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM. Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. The primary end point is the composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation. The main secondary study end points are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, Quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia\u002Fventricular fibrillation episodes, LV function, and exercise tolerance. CASTLE-VT will randomize 160 patients with a follow up period of 2 years.",[28,29,30,31,32,33],"Heart Failure","Arrhythmia, Ventricular","Cardiomyopathy Ischemic","Catheter Ablation","Heart Transplantation","Left Ventricular Assist Device","RECRUITING","2024-12-01",{"date":37,"type":38},"2024-12-04","ACTUAL",{"date":40,"type":38},"2024-09-13",{"date":42,"type":22},"2027-01-01",{"name":44,"class":45},"Heart and Diabetes Center North-Rhine Westfalia","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100559958","prospective-wcd-post-cabg-registry-cabg-registry-100559958","NCT06570902","Prospective WCD Post CABG Registry (CABG Registry)","Prospective WCD Post CABG Registry","Inclusion Criteria\n\n* Patient underwent first-time CABG surgery \\\u003C10 days before enrollment.\n* Patient is prescribed WCD for a primary reason of HF with reduced EF \\\u003C 35% measured after surgery but before hospital discharge.\n* Patient is ≥18 years old\n\nExclusion Criteria:\n\n* Patients having combination CABG surgery with heart valve repair.\n* Patients with prior CABG.\n* Patients who have an active unipolar pacemaker.\n* Patients with a physical or mental condition that could impair their ability to properly interact with the WCD.\n\nPatients currently participating in an interventional clinical study. Patients with any skin condition that would prevent wearing the device. Patients with an advanced directive prohibiting resuscitation.",{"count":55,"type":22},910,"12 Months","OBSERVATIONAL","The primary objective is to observe the rate of recovery of ventricular function (EF\\>35%) after first-time coronary artery bypass graft surgery in patients who were prescribed the wearable cardioverter defibrillator (WCD) post-surgery prior to being discharged after hospitalization as part of standard clinical care.",[30,60,61,62],"Cardiomyopathies","Cardiovascular Diseases","Heart Disease, Ischemic","2024-10-31",{"date":65,"type":38},"2024-11-04",{"date":67,"type":38},"2024-09-23",{"date":69,"type":22},"2030-05",{"name":71,"class":72},"Zoll Medical Corporation","INDUSTRY",4]